The new anti-amyloid drugs for AD are interesting, but an efficacy of 3 points on a 144 scale (2%) does not sound so impressive. We also need to understand ARIA much more
Læs også
@MbhLlen Ligesom med COVID-19. Og ja hun misinformerer.
- Andreas Andersen
- 10. september 2022
- 0
@MbhLlen Ligesom med COVID-19. Og ja hun misinformerer.
@jcpersen @regionerne Det tror jeg der er mange afdelinger der ikke har kapacitet til
- Andreas Andersen
- 14. december 2021
- 0
@jcpersen @regionerne Det tror jeg der er mange afdelinger der ikke har kapacitet til
@VibekeVind @LiseAndersen6 Jo, men nu har du jo endnu ikke fortalt hvilken livreddende behandling Jesper Mehlsen har givet?
- Andreas Andersen
- 10. juni 2022
- 0
@VibekeVind @LiseAndersen6 Jo, men nu har du jo endnu ikke fortalt hvilken livreddende behandling Jesper Mehlsen har givet?
Agree that we need to characterize ARIA better and make sure doctors know how to predict it and manage it. On the efficacy, I struggle to see why such a change ( which is measurable and consistent on a clinical scale which is not so sensitive to begin with) should be meaningless.
If the clinical scale is so bad, then it might not be the best ending point to show efficacy of the drug, that can balance the side effects, expensive price and changes in diagnostic setup of AD. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients and relatives.